Provenge CMO PharmaCell contracted for 2nd product
PharmaCell, the CMO that makes Provenge for Dendreon in Europe, has agreed to buy a facility from TiGenix to add capacity and a manufacturing contract for a second commercial product.
Archives for January 24, 2014
Lonza confident manufacturing capacity will be filled, post Teva biosimilar JV
The end of Lonza’s biosimilar joint venture with Teva will not affect manufacturing capacity, the firm says, as it reports a drop in overall revenue for 2013.